Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2015

01.01.2015 | Editorial

Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis

verfasst von: Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

Nonalcoholic fatty liver disease (NAFLD) is an ever-growing problem in the developed and developing worlds, affecting 15–40 % of the population [1]. Once regarded as a benign condition, NAFLD is the leading cause of cryptogenic cirrhosis and cryptogenic hepatocellular carcinoma (HCC) [2], and the third most frequent indication for liver transplantation [3]. …
Literatur
1.
Zurück zum Zitat Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61:409–415.PubMedCrossRef Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61:409–415.PubMedCrossRef
2.
Zurück zum Zitat Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–974.PubMedCrossRef Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–974.PubMedCrossRef
3.
Zurück zum Zitat Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.PubMedCrossRef Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.PubMedCrossRef
4.
Zurück zum Zitat Chan HL, de Silva HJ, Leung NW, et al. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol. 2007;22:801–808.PubMedCrossRef Chan HL, de Silva HJ, Leung NW, et al. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol. 2007;22:801–808.PubMedCrossRef
5.
Zurück zum Zitat Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis. 2007;11:173–189, x. Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis. 2007;11:173–189, x.
6.
Zurück zum Zitat Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.PubMedCrossRef Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.PubMedCrossRef
7.
Zurück zum Zitat Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–462.PubMedCrossRef Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–462.PubMedCrossRef
9.
Zurück zum Zitat Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.PubMedCrossRef Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.PubMedCrossRef
10.
Zurück zum Zitat de Ledinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–918.PubMedCrossRef de Ledinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–918.PubMedCrossRef
11.
Zurück zum Zitat Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–910.PubMedCrossRef Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–910.PubMedCrossRef
12.
Zurück zum Zitat Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat. 2012;19:244–253.PubMedCrossRef Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat. 2012;19:244–253.PubMedCrossRef
14.
Zurück zum Zitat Beaugrand M, de Ledinghen V, Douvin C, et al. Validation of controlled attenuation parameter (CAP) as a non-invasive marker of steatosis in 228 patients with chronic liver disease from various causes. J Hepatol. 2010;52:S35–S36. Beaugrand M, de Ledinghen V, Douvin C, et al. Validation of controlled attenuation parameter (CAP) as a non-invasive marker of steatosis in 228 patients with chronic liver disease from various causes. J Hepatol. 2010;52:S35–S36.
15.
Zurück zum Zitat Beaugrand M, Ziol M, de Ledinghen V, et al. Controlled attenuation parameter: A novel FibroScan®-based tool to detect and quantify steatosis. Preliminary study in patient with alcoholoc and non alcoholic fatty liver disease. J Hepatol. 2010;52:S158–S159. Beaugrand M, Ziol M, de Ledinghen V, et al. Controlled attenuation parameter: A novel FibroScan®-based tool to detect and quantify steatosis. Preliminary study in patient with alcoholoc and non alcoholic fatty liver disease. J Hepatol. 2010;52:S158–S159.
16.
Zurück zum Zitat Chon YE, Jung KS, Kim KJ, et al. Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-014-3293-1. Chon YE, Jung KS, Kim KJ, et al. Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-014-3293-1.
17.
Zurück zum Zitat Mi YQ, Shi QY, Zu L, et al. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan(®): validation in chronic hepatitis B. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-014-3341-x. Mi YQ, Shi QY, Zu L, et al. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan(®): validation in chronic hepatitis B. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-014-3341-x.
18.
Zurück zum Zitat Wong GL, Wong VW, Choi PC, et al. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2009;24:1002–1007.PubMedCrossRef Wong GL, Wong VW, Choi PC, et al. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2009;24:1002–1007.PubMedCrossRef
19.
Zurück zum Zitat Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16:36–44.PubMedCrossRef Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16:36–44.PubMedCrossRef
20.
Zurück zum Zitat Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533–540.PubMedCrossRef Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533–540.PubMedCrossRef
21.
Zurück zum Zitat Wong GL, Chan HL, Yu Z, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39:883–893.PubMedCrossRef Wong GL, Chan HL, Yu Z, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39:883–893.PubMedCrossRef
22.
Zurück zum Zitat Wong GL, Wong VW, Choi PC, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58:111–117.PubMedCrossRef Wong GL, Wong VW, Choi PC, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58:111–117.PubMedCrossRef
23.
Zurück zum Zitat Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339–345.PubMedCrossRef Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339–345.PubMedCrossRef
Metadaten
Titel
Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis
verfasst von
Grace Lai-Hung Wong
Vincent Wai-Sun Wong
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2015
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3429-3

Weitere Artikel der Ausgabe 1/2015

Digestive Diseases and Sciences 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.